Histogenics Corporation develops restorative cell therapies that would offer rapid-onset pain relief and restored function. The company was founded in 2000 and is headquartered in Waltham, Massachusetts.
Industry, Sector and Symbol
Industry Surgical appliances & supplies
Sub-IndustryN/A
SectorMedical
Phone781-547-7900
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees49
Next Earnings Date11/14/2019 (Estimated)
OptionableNot Optionable
Histogenics (NASDAQ:HSGX) Frequently Asked Questions
What is Histogenics' stock symbol?
Histogenics trades on the NASDAQ under the ticker symbol "HSGX."
How were Histogenics' earnings last quarter?
Histogenics Corp (NASDAQ:HSGX) posted its quarterly earnings data on Friday, August, 9th. The biotechnology company reported ($0.03) EPS for the quarter, missing the consensus estimate of ($0.01) by $0.02. View Histogenics' Earnings History.
When is Histogenics' next earnings date?
What price target have analysts set for HSGX?
1 brokers have issued 1 year price targets for Histogenics' stock. Their forecasts range from $1.00 to $1.00. On average, they anticipate Histogenics' stock price to reach $1.00 in the next year. This suggests a possible upside of 354.5% from the stock's current price. View Analyst Price Targets for Histogenics.
What is the consensus analysts' recommendation for Histogenics?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Histogenics in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Histogenics.
What are Wall Street analysts saying about Histogenics stock?
Here are some recent quotes from research analysts about Histogenics stock:
- 1. According to Zacks Investment Research, "Histogenics Corporation is a regenerative medicine company. It is focused on developing and commercializing products in the musculoskeletal segment. The company is developing NeoCart(R) product to provide treatment in the orthopedic space. Histogenics Corporation is headquartered in Waltham, Massachusetts. " (1/15/2019)
- 2. HC Wainwright analysts commented, "Valuation and risks to our investment thesis. Our price target of $21/share is based on an equally-weighted composite of: (a) $12.6/share, as a 35x multiple of taxed and diluted $3.85 discounted back to FY19 at 20% (in line with the expected PE multiple and discount rate of an early development-stage biotechnology company); and (b) an NPV of $29.3/ share (discounted cash flow analysis using a 12% discount rate and 3.5% growth rate, in line with the expected discount and growth parameters of an early development-stage biotechnology company). Translate Bio, Inc." (12/24/2018)
Has Histogenics been receiving favorable news coverage?
News articles about HSGX stock have trended somewhat negative on Sunday, InfoTrie reports. The research group scores the sentiment of press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Histogenics earned a coverage optimism score of -1.3 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Histogenics.
Who are some of Histogenics' key competitors?
What other stocks do shareholders of Histogenics own?
Who are Histogenics' key executives?
Histogenics' management team includes the folowing people:
- Mr. Adam D. Gridley, Interim Pres, CEO Treasurer, Sec., Consultant & Director (Age 47)
- Mr. Jonathan I. Lieber, Interim Chief Financial Officer (Age 49)
- Mr. Stephen R. Kennedy, Consultant (Age 62)
When did Histogenics IPO?
(HSGX) raised $60 million in an initial public offering on Wednesday, December 3rd 2014. The company issued 4,300,000 shares at a price of $13.00-$15.00 per share. Cowen and Company, Needham & Company and Canaccord Genuity served as the underwriters for the IPO and BTIG was co-manager.
Who are Histogenics' major shareholders?
Histogenics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include CVI Holdings LLC (36.16%) and Vanguard Group Inc. (1.06%). Company insiders that own Histogenics stock include Adam Gridley and Randal J Kirk. View Institutional Ownership Trends for Histogenics.
Which major investors are selling Histogenics stock?
Which major investors are buying Histogenics stock?
How do I buy shares of Histogenics?
Shares of HSGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Histogenics' stock price today?
One share of HSGX stock can currently be purchased for approximately $0.22.
How big of a company is Histogenics?
Histogenics has a market capitalization of $20.81 million. The biotechnology company earns $-8,640,000.00 in net income (profit) each year or ($0.79) on an earnings per share basis. Histogenics employs 49 workers across the globe.View Additional Information About Histogenics.
What is Histogenics' official website?
How can I contact Histogenics?
Histogenics' mailing address is 830 WINTER STREET 3RD FLOOR, WALTHAM MA, 02451. The biotechnology company can be reached via phone at 781-547-7900 or via email at [email protected]
MarketBeat Community Rating for Histogenics (NASDAQ HSGX)
MarketBeat's community ratings are surveys of what our community members think about Histogenics and other stocks. Vote "Outperform" if you believe HSGX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HSGX will underperform the S&P 500 over the long term. You may vote once every thirty days.
